Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small ce...
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-07-30
- Target Recruit Count
- 235
- Registration Number
- NCT06412471
- Locations
- 🇨🇳
Institute of The Hunan Cancer Hospital, Changsha, China
Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir
- Conditions
- Interventions
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Xiangya Hospital of Central South University
- Target Recruit Count
- 64
- Registration Number
- NCT06399926
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-04-30
- Target Recruit Count
- 44
- Registration Number
- NCT06391008
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 24
- Registration Number
- NCT06364917
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Diagnosis of Leptomeningeal Metastasis and the Monitoring of Intrathecal Chemotherapy Efficacy in NSCLC
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 60
- Registration Number
- NCT06346977
- Locations
- 🇨🇳
Union hospital, Wuhan, Hubei, China
Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure
- Conditions
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT06334757
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 500
- Registration Number
- NCT06333951
- Locations
- 🇯🇵
Aichi Cancer Center, Nagoya-shi, Aichi, Japan
🇺🇸Virginia Cancer Specialists PC, Fairfax, Virginia, United States
🇺🇸Northwest Medical Specialties, PLLC, Tacoma, Washington, United States
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Hyogo Medical University
- Target Recruit Count
- 25
- Registration Number
- NCT06318286
- Locations
- 🇯🇵
Hyogo Medical University Hospital, Nishinomiya, Hyogo, Japan
The Dynamic Monitoring of Cerebrospinal Fluid ctDNA
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Jiangsu Province Nanjing Brain Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06315686
- Locations
- 🇨🇳
Nanjing Brain Hospital, Suzhou, Jiangsu, China
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 780
- Registration Number
- NCT06312137
- Locations
- 🇨🇳
Zhongshan Hospital of Fudan University ( Site 1325), Shangai, Shanghai, China
🇫🇷Groupe hospitalier Paris saint Joseph. ( Site 1807), Paris, Ile-de-France, France
🇫🇷Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 1810), Clermont-Ferrand, Puy-de-Dome, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.